Skip to main content
  • EN
  • FI
  • SV
Login

Main navigation

  • About FinnGen
    • Summary & Goals
      • Goals
      • FinnGen 1-2
      • FinnGen 3 (2023-2027)
    • Consortium
      • Partners
      • Funding
      • Governance
      • Steering Committee Members
      • Scientific Committee Members
      • Teams
      • Collaboration
    • Impact
      • National Impact
      • National Research Network
      • Open Science
      • Research Highlights
    • Why Finland?
      • Biobank Network
      • Legislative Review
      • National Registries
      • Population Genetic History
      • Industry partners
    • Mediabank
  • For Researchers
    • Research Activities
      • Core Analyses
      • Disease Task Forces
      • Expansion Areas
      • Global Initiatives
    • Cohort and Data
      • Register Data
      • Basic Characteristics
      • Clinical Endpoints
      • Genetic Data
      • Laboratory Values
      • Other Phenotype Data
      • Recruitment
      • Other Biological Data
      • Data Available
    • Accessing Data, Results & Tools
      • Access results
      • Computing environment
      • How we collaborate
      • Partner researchers
      • Public data releases
      • Tools
    • Publications
    • Researcher FAQ
  • For Participants
    • Participation
      • Study Participants
      • Biobanks' Role in FinnGen
      • Biobank Contact Information
      • Recall Studies
      • Questions and answers
    • Data Protection and Security
      • Data Protection
      • Data Security
      • Sample & Data Flow
      • Data Protection Statement
    • Significance
      • Videos
  • News
  • EN
  • FI
  • SV

Links

  • PheWeb
  • Risteys
  • Meta-analysis Pheweb (FG-MVP-UKBB)
  • FinnGen handbook
  • Meta-analysis Pheweb (FG-UKBB)
  • Coding variant browser
  • Endpoint Browser
  • FinnGen GITHUB
  • LAVAA volcano plot
  • Multiple Manhattan Plot
  • Variant Cluster Corrector
  • Variant Cluster Call Corrector
Breadcrumb
  1. Home

Comprehensive Druggable Genome-Wide Mendelian Randomization Reveals Therapeutic Targets for Kidney Diseases

Submitted by Frida Mäkelä on Mon, 06/17/2024 - 15:01
  • Read more about Comprehensive Druggable Genome-Wide Mendelian Randomization Reveals Therapeutic Targets for Kidney Diseases

Unraveling the role of proteins in dementia: insights from two UK cohorts with causal evidence

Submitted by Frida Mäkelä on Mon, 06/17/2024 - 14:58
  • Read more about Unraveling the role of proteins in dementia: insights from two UK cohorts with causal evidence

The Causal Effect of Intrapancreatic Fat Deposition on Acute and Chronic Pancreatitis: A Mendelian Randomization Study

Submitted by Frida Mäkelä on Mon, 06/17/2024 - 14:41
  • Read more about The Causal Effect of Intrapancreatic Fat Deposition on Acute and Chronic Pancreatitis: A Mendelian Randomization Study

Genome-wide association study of anterior uveitis

Submitted by Frida Mäkelä on Mon, 06/17/2024 - 14:26
  • Read more about Genome-wide association study of anterior uveitis

Anaesthesia and delirium: a Mendelian randomization study

Submitted by Frida Mäkelä on Mon, 06/17/2024 - 14:23
  • Read more about Anaesthesia and delirium: a Mendelian randomization study

Multi-organ imaging-derived polygenic indexes for brain and body health

Submitted by Frida Mäkelä on Mon, 06/17/2024 - 14:12
  • Read more about Multi-organ imaging-derived polygenic indexes for brain and body health

Associations of inflammatory cytokines with palmoplantar pustulosis: a bidirectional Mendelian randomization study

Submitted by Frida Mäkelä on Mon, 06/17/2024 - 14:05
  • Read more about Associations of inflammatory cytokines with palmoplantar pustulosis: a bidirectional Mendelian randomization study

Validation of L-type calcium channel blocker amlodipine as a novel ADHD treatment through cross-species analysis, drug-target Mendelian randomization, and clinical evidence from medical records

Submitted by Frida Mäkelä on Mon, 06/17/2024 - 11:48
  • Read more about Validation of L-type calcium channel blocker amlodipine as a novel ADHD treatment through cross-species analysis, drug-target Mendelian randomization, and clinical evidence from medical records

Contribution of leukocyte telomere length to cardiovascular disease onset from genome-wide cross-trait analysis

Submitted by Frida Mäkelä on Mon, 06/17/2024 - 11:36
  • Read more about Contribution of leukocyte telomere length to cardiovascular disease onset from genome-wide cross-trait analysis

Elucidating the Epigenetic Landscape of Type 2 Diabetes Mellitus: A Multi-Omics Analysis Revealing Novel CpG Sites and Their Association with Cardiometabolic Traits

Submitted by Frida Mäkelä on Mon, 06/17/2024 - 11:15
  • Read more about Elucidating the Epigenetic Landscape of Type 2 Diabetes Mellitus: A Multi-Omics Analysis Revealing Novel CpG Sites and Their Association with Cardiometabolic Traits

Pagination

  • First page « First
  • Previous page ‹ Previous
  • …
  • Page 266
  • Page 267
  • Page 268
  • Page 269
  • Current page 270
  • Page 271
  • Page 272
  • Page 273
  • Page 274
  • …
  • Next page Next ›
  • Last page Last »
Subscribe to

Contact us

Contact person
finngen-info@helsinki.fi
Follow us on Bluesky
@finngen.bsky.social

Lead organisations

The University of Helsinki is the organization responsible for the FinnGen research project. The Finnish consortium partners include all Finnish public biobanks and their background organisations, so the project covers the whole of Finland. All partners are listed on this page.

About the website

Accessibility statement